Literature DB >> 1752777

Human granulocyte-macrophage colony-stimulating factor is a growth factor active on human ovarian cancer cells.

G Cimoli1, P Russo, G Billi, G L Mariani, E Rovini, M Venturini.   

Abstract

Human granulocyte-macrophage colony-stimulating factor (GM-CSF) is a regulatory glycoprotein that stimulates the production of granulocytes and macrophages from committed hematopoietic progenitor cells both in vitro and in vivo. In this report, we show that recombinant human GM-CSF enhances colony formation by nonhematopoietic human ovarian cancer cell lines, IGROV-1, A2774, ME-180, Pa-1 and A2780. GM-CSF also enhanced the colony formation by cells obtained from fresh ascites of a patient with ovarian mucinous cystadenocarcinoma and a patient with serous papillary ovarian carcinoma. Our observations were made with GM-CSF concentrations between 0.1 to 1 ng/ml; these concentrations are equivalent to the dosages generally used for bone marrow recovery after chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1752777      PMCID: PMC5918337          DOI: 10.1111/j.1349-7006.1991.tb01779.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  11 in total

1.  Characterization of the human granulocyte-macrophage colony-stimulating factor receptor.

Authors:  J DiPersio; P Billing; S Kaufman; P Eghtesady; R E Williams; J C Gasson
Journal:  J Biol Chem       Date:  1988-02-05       Impact factor: 5.157

Review 2.  The granulocyte-macrophage colony-stimulating factors.

Authors:  D Metcalf
Journal:  Science       Date:  1985-07-05       Impact factor: 47.728

Review 3.  Hemopoietins in oncology: factoring out myelosuppression.

Authors:  J D Griffin
Journal:  J Clin Oncol       Date:  1989-02       Impact factor: 44.544

4.  Various human hematopoietic growth factors (interleukin-3, GM-CSF, G-CSF) stimulate clonal growth of nonhematopoietic tumor cells.

Authors:  W E Berdel; S Danhauser-Riedl; G Steinhauser; E F Winton
Journal:  Blood       Date:  1989-01       Impact factor: 22.113

5.  Human granulocyte colony-stimulating factor: biologic activities and receptor characterization on hematopoietic cells and small cell lung cancer cell lines.

Authors:  B R Avalos; J C Gasson; C Hedvat; S G Quan; G C Baldwin; R H Weisbart; R E Williams; D W Golde; J F DiPersio
Journal:  Blood       Date:  1990-02-15       Impact factor: 22.113

6.  Human granulocyte-macrophage colony-stimulating factor is a growth factor active on a variety of cell types of nonhemopoietic origin.

Authors:  S Dedhar; L Gaboury; P Galloway; C Eaves
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

7.  Nonhematopoietic tumor cells express functional GM-CSF receptors.

Authors:  G C Baldwin; J C Gasson; S E Kaufman; S G Quan; R E Williams; B R Avalos; A F Gazdar; D W Golde; J F DiPersio
Journal:  Blood       Date:  1989-03       Impact factor: 22.113

8.  Doxorubicin cytotoxicity to P388 lymphocytic leukemia as determined by alkaline elution and established assays.

Authors:  P Russo; R E Favoni; D Zarcone; L Miglietta; M Peluso; A Nicolin; F Bignone; S Parodi
Journal:  Anticancer Res       Date:  1986 Nov-Dec       Impact factor: 2.480

9.  A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action.

Authors:  G B Mills; C May; M McGill; C M Roifman; A Mellors
Journal:  Cancer Res       Date:  1988-03-01       Impact factor: 12.701

10.  High-affinity binding of granulocyte-macrophage colony-stimulating factor to normal and leukemic human myeloid cells.

Authors:  J C Gasson; S E Kaufman; R H Weisbart; M Tomonaga; D W Golde
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

View more
  1 in total

Review 1.  Hematopoietic growth factors and treatment of testicular cancer: biological interactions, routine use and dose-intensive chemotherapy.

Authors:  C Bokemeyer; M A Kuczyk; H Köhne; H Einsele; B Kynast; H J Schmoll
Journal:  Ann Hematol       Date:  1996-01       Impact factor: 3.673

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.